PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1127422
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1127422
Absorbable tissue spacer Market size was valued at USD 102.1 Million in 2021, growing at a CAGR of 5.1% from 2022 to 2028.
In order to provide adequate protection and to create a strong protective barrier during radiotherapy, absorbable tissue spacers refer to bioabsorbable tissue spacers made of a variety of materials, including nonwoven fabrics, polymers, hydrogels, and a few injectable materials. This allows for a more concentrated effect on the target tissues.
The rising incidence of cancer and the benefits of tissue spacers are a couple of the factors propelling market expansion. One of the biggest causes of death worldwide is cancer. The disease has grown significantly over the past few decades, and during the coming years, it is anticipated to increase quickly. Over the next twenty years, the World Health Organization (WHO) predicts that the cancer rate will rise to 70%.
The cornerstone for the growth of the absorbable tissue spacer market is the soaring demand for radiation therapy against the backdrop of rising cancer morbidities relative to other chronic diseases in both developed and underdeveloped economies. Additionally, strict legal regulations will continue to be in place to control the release of high-energy radiation during radiotherapy treatments and ensure patient safety, which is expected to encourage manufacturers to conduct clinical trials after consulting with specialists. The prevalence of cancer is still on the rise, and oncologists and dosimetrists are still deeply interested in finding effective ways to remove diseased tissues. The market is also anticipated to be driven by the rising prevalence of a number of lifestyle disorders since biomarkers are essential for risk assessment, early diagnosis, and efficient treatment monitoring.
The Worldwide Absorbable tissue spacer Industry is categorized on the basis of Type, Application, End User, and Region. The market is divided into four categories based on product type: Biodegradable Hyaluronic Acid Spacer, Hydrogel-Based Spacer, Biodegradable Balloon Spacer & Crystal-Based Spacer. Hydrogel-Based Spacer held the majority of the market share in terms of revenue. Approximately 3/4 of all sales are made up of hydrogel-based absorbable tissue spacers. According to the paper, the hydrogel-based Spacer is one of the few absorbable tissue spacers which is approved by governments worldwide and is quickly becoming a crucial part of radiation for prostate cancer.
The market is divided into two categories based on application: Radiotherapy & Infection Management. The film and sheet segment accounted for the largest share, over 77.5% in 2021 of the Absorbable tissue spacer market 2021. X-rays and other high-energy rays are used in particle treatment and radiation therapy to kill the malignant cells in the tumor or other target location. However, it also eliminates healthy and normal cells close to the target cell area. It may cause a number of adverse reactions in the body, including dry mouth and nausea. Researchers have developed absorbable tissue spacers to address these problems and mitigate their negative effects. This has led to the makers' introduction of virtually absorbable tissue spacers using MRI and CT imaging techniques. These spacers may scan the region and provide the doctors with accurate information, enabling them to make better diagnostic choices, such as determining the precise number of absorbable tissue spacers required for implantation.
The global market for Absorbable tissue spacers is made of a number of both international and local producers, making it a highly competitive sector in the world. Some of the leading strategies adopted by corporations to expand their market share include new product launches, agreements, distribution network development, R&D spending, and mergers and acquisitions. Moreover, since the Prostate-rectum hydrogel spacer is a relatively safe technical procedure that is well tolerated and has a high technical success rate, thus its application has also increased recently. In November 2020, paceOAR Vue Hydrogel, a radiopaque perirectal spacer for radiation therapy, got approval for sale in the United States for use in patients with prostate cancer receiving radiotherapy.
The scope of this report covers the market by its major segments, which include as follows: